Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Special Protocol Rescissions Get U.S. Capitol, Venture Capital Attention

This article was originally published in The Pink Sheet Daily

Executive Summary

House Appropriations Committee wants FDA to provide more justification when it changes a special protocol assessment.


Related Content

Gene Therapy Guidance From US FDA Likely Needs Updating Sooner Rather Than Later
'Combination Product Agreement Meetings' Coming Soon From US FDA
US FDA Preparing For New 'Combination Product Agreement Meetings'
Compassionate Use Study Added To House Approps Orders
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Should FDA Be Forced To Consider Development Time And Cost?
Northera Review Shows Regulatory Challenges In Difficult Therapeutic Space


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts